Quantcast
Home » News
Home » News

Takeover target Shire promises strong growth

Published June 23, 2014 9:41 am
This is an archived article that was published on sltrib.com in 2014, and information in the article may be outdated. It is provided only for personal research purposes and may not be reprinted.

London • Takeover target Shire PLC is highlighting its potential as a standalone company, offering investors a rosy projection of its earnings potential that it believes is not reflected in either its share price or the takeover proposal made by U.S.-based drugmaker AbbVie.

Chief Executive Flemming Ornskov told analysts Monday that Shire should remain independent, and that it expects to more than double its 2013 annual product sales to $10 billion by 2020.

The company, which is known for its rare disease drugs, has rejected an unsolicited $46.2 billion offer from AbbVie Inc., arguing it fundamentally undervalues the company. Shire has rejected three overtures.



The offer comes at a time of intense speculation in the industry, as drugmakers look to grow or eliminate noncore assets while focusing on strengths.

 

 

 

USER COMMENTS
Reader comments on sltrib.com are the opinions of the writer, not The Salt Lake Tribune. We will delete comments containing obscenities, personal attacks and inappropriate or offensive remarks. Flagrant or repeat violators will be banned. If you see an objectionable comment, please alert us by clicking the arrow on the upper right side of the comment and selecting "Flag comment as inappropriate". If you've recently registered with Disqus or aren't seeing your comments immediately, you may need to verify your email address. To do so, visit disqus.com/account.
See more about comments here.
comments powered by Disqus